EW's new late-breaking clinical data shows early intervention in AS may slash significant costs and improve patient outcomes.

The development is expected to boost both the company’s Transcatheter Aortic Valve Replacement (“TAVR ... premium RESILIA portfolio, including INSPIRIS, MITRIS and KONECT.

Edwards Lifesciences (NYSE: EW) today announced new economic and clinical evidence on severe aortic stenosis (AS).

As in the SMART trial, early hemodynamic differences have yet to result in a clinical impact—but it may just be a matter of ...

Meril Life Sciences today announced one-year results from a pivotal trial evaluating its balloon-expandable Myval THV system.

While visiting Utah, Christine Seppi experienced sudden, severe abdominal and back pain. A rare diagnosis—an abdominal aortic ...

Edwards Lifesciences Corp. released new economic and clinical data on severe aortic stenosis (AS) demonstrating intervening in a patient with the disease before symptoms develop can reduce costs to ...

The study found that early intervention led to an 80% reduction in heart failure hospitalisations one year after treatment.